Status:
UNKNOWN
Nicotinamide to Prevent Delirium
Lead Sponsor:
University of Chile
Collaborating Sponsors:
Fondo Nacional de Desarrollo Científico y Tecnológico, FONDECYT (Chile).
Conditions:
Delirium Confusional State
Eligibility:
All Genders
65+ years
Phase:
NA
Brief Summary
Delirium is defined as an acute change in mental status characterized by fluctuating disturbances of consciousness, attention, cognition, and perception, usually secondary to acute injuries such as tr...
Eligibility Criteria
Inclusion
- Older than 65 years old.
- Newly admitted due to suspected coronavirus disease (COVID-19) under study.
- To have less than 24 hours from the hospitalization at the moment of randomization.
- Able to take medicine orally.
- Signed an informed consent.
Exclusion
- An expected stay or life expectancy of less than 48 hours.
- Severe liver dysfunction or Lewy body disease.
- Syndromes associated with alcohol dependency and drug abuse.
- Psychotic or bipolar disorders receiving treatment with antipsychotics.
- Delirious at admission Patients.
- Documented viral infections.
Key Trial Info
Start Date :
January 21 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 30 2022
Estimated Enrollment :
146 Patients enrolled
Trial Details
Trial ID
NCT04725253
Start Date
January 21 2021
End Date
April 30 2022
Last Update
January 26 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital Clínico Universidad de Chile
Santiago, Chile